<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-lorazepam.xml</id>
  <title>Recalls Watch: Lorazepam</title>
  <link rel="self" href="https://recalls.watch/feed/substance-lorazepam.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2025-08-06T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/97294/</id>
    <title>Hikma Pharmaceuticals USA Inc.: Lorazepam Injection</title>
    <link href="https://recalls.watch/recall/fda/97294/"/>
    <updated>2025-08-06T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96308/</id>
    <title>Safecor Health, LLC: Ergocalciferol - Vitamin D Supplement - 10 mcg and 4 more</title>
    <link href="https://recalls.watch/recall/fda/96308/"/>
    <updated>2025-03-12T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Defective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96151/</id>
    <title>The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories: Lorazepam Tablets and 2 more</title>
    <link href="https://recalls.watch/recall/fda/96151/"/>
    <updated>2025-02-26T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/91788/</id>
    <title>Akorn, Inc.: Atropine Sulfate Ophthalmic Solution and 85 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=91788"/>
    <updated>2023-06-07T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Firm went out of business and could no longer continue stability studies.</summary>
  </entry>
</feed>
